MedTrace Logo

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01739582 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2014-04-16

No results posted yet for this study

Summary

To determine the safety profile of Androxal in men with secondary hypogonadism.

Conditions

  • Secondary Hypogonadism

Interventions

DRUG

Androxal

Sponsors & Collaborators

  • Repros Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01739582 on ClinicalTrials.gov